Details for Patent: 9,861,631

Title:	Methods and compositions for safe and effective treatment of erythema
Abstract:	Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight of brimonidine and a pharmaceutically acceptable carrier.
Inventor(s):	Graeber; Michael (Lawrenceville, NJ), Loesche; Christian (Hegenheim, FR), Freidenreich; Philip (Yardley, PA), Liu; Yin-sang (Princeton Junction, NJ), Leoni; Matthew James (Titusville, NJ)
Assignee:	Galderma Laboratories, L.P. (Fort Worth, TX)
Filing Date:	Apr 06, 2015
Application Number:	14/679,598
Claims:	1. A method of treating facial erythema associated with rosacea in a subject in need thereof, comprising once daily topically administering to a skin area of the subject affected by the facial erythema a topical composition comprising, relative to the total weight of the composition: 0.5% by weight of brimonidine tartrate; about 8.0% to about 30.0% by weight in total of one or more polyols; about 0.20% to about 4.0% by weight of a gelling agent; and a pharmaceutically acceptable carrier, wherein the topical administration results in more reduction of the facial erythema compared to a vehicle control as measured by a 12 hour success profile evaluated on both Clinician's Erythema Assessment scores and Patient's Self Assessment scales without causing unacceptable drug related adverse events, and the 12 hour success profile comprises at least a 1-grade improvement of the facial erythema. 2. The method of claim 1, wherein the 12 hour success profile further comprises about 1 hour to about 8 hours of a 2-grade improvement of the facial erythema. 3. The method of claim 1, wherein the 12 hour success profile further comprises about 3 hours to about 6 hours of a 2-grade improvement of the facial erythema. 4. The method of claim 1, wherein the gelling agent comprises a carbomer, and the topical composition comprises about 0.5% to about 2.0% by weight of the carbomer relative to the total weight of the composition. 5. The method of claim 4, wherein the carbomer is selected from the group consisting of carbomer 934P, carbomer 974P, and carbomer 980. 6. The method of claim 5, wherein the topical composition comprises a first polyol and a second polyol, and the amount of each of the first and second polyols in the composition is independently about 4 to 15% by weight relative to the total weight of the composition. 7. A method of treating facial erythema associated with rosacea in a subject in need thereof, comprising once daily topically administering to a skin area of the subject affected by the facial erythema a topical composition comprising, relative to the total weight of the composition: 0.5% by weight of brimonidine tartarate; about 5.0% to about 30.0% by weight of at least one polyol; about 0.5% to about 2.0% by weight of a gelling agent; and a pharmaceutically acceptable carrier, wherein the gelling agent comprises a carbomer selected from the group consisting of carbomer 934P, carbomer 974P, and carbomer 980, and wherein the topical administration results in more reduction of the facial erythema compared to a vehicle control as measured by a 12 hour success profile evaluated on both Clinician's Erythema Assessment scores and Patient's Self Assessment scales without causing unacceptable drug related adverse events, and the 12 hour success profile comprises at least a 1-grade improvement of the facial erythema and about 1 hour to about 8 hours or about 3 hours to about 6 hours of a 2-grade improvement of the facial erythema. 8. The method of claim 7, wherein the topical composition further comprises a preservative selected from the group consisting of sodium benzoate, phenoxyethanol, benzyl alcohol, methylparaben, imidazolidinyl urea and diazolidinyl urea.